11-dehydro-txb2

Introduction

To understand associated biological information of 11-dehydro-txb2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 11-dehydro-txb2?

11-dehydro-txb2 is suspected in Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-Dependent and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 11-dehydro-txb2

MeSH term MeSH ID Detail
Inflammation D007249 119 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Atherosclerosis D050197 85 associated lipids
Hyperlipidemias D006949 73 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Asthma D001249 52 associated lipids
Thrombosis D013927 49 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Albuminuria D000419 18 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Polycythemia Vera D011087 13 associated lipids
Death, Sudden, Cardiac D016757 12 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Renal Artery Obstruction D012078 8 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Per page 10 20 | Total 20

PubChem Associated disorders and diseases

What pathways are associated with 11-dehydro-txb2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

What functions are associated with 11-dehydro-txb2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

What genes are associated with 11-dehydro-txb2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with 11-dehydro-txb2

Download all related citations
Per page 10 20 50 100 | Total 283
Authors Title Published Journal PubMed Link
Schlit AF et al. Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives. 1995 Contraception pmid:7750285
Nüsing RM et al. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide. 2001 Clin. Pharmacol. Ther. pmid:11673754
Renda G et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. 2006 Clin. Pharmacol. Ther. pmid:16952493
Lee CR et al. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. 2008 Clin. Pharmacol. Ther. pmid:17495879
Cipollone F et al. Effects of nabumetone on prostanoid biosynthesis in humans. 1995 Clin. Pharmacol. Ther. pmid:7554708
Oosaki R et al. Correlation among urinary eosinophil protein X, leukotriene E4, and 11-dehydrothromboxane B2 in patients with spontaneous asthmatic attack. 1998 Clin. Exp. Allergy pmid:9761018
Gonçalves LH et al. Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels. 2014 Clin. Chim. Acta pmid:24316050
Gonçalves LH et al. Urinary 11-dehydro thromboxane B₂ levels in type 2 diabetic patients before and during aspirin intake. 2011 Clin. Chim. Acta pmid:21510926
Lowe FJ et al. Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. 2009 Clin. Chem. Lab. Med. pmid:19676143
Djurup R et al. Rapid, direct enzyme immunoassay of 11-keto-thromboxane B2 in urine, validated by immunoaffinity/gas chromatography-mass spectrometry. 1993 Clin. Chem. pmid:8252718
Karon BS et al. Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. 2008 Clin. Chem. pmid:18420732
Fiorucci S et al. NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. 2002 Circulation pmid:12473561
Rouvier J et al. Aspirin resistance. 2002 Circulation pmid:12473569
Minuz P et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 2002 Circulation pmid:12451006
Hennekens CH et al. Terms and conditions: semantic complexity and aspirin resistance. 2004 Circulation pmid:15381661
Belton O et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. 2000 Circulation pmid:10952950
Reilly M et al. Modulation of oxidant stress in vivo in chronic cigarette smokers. 1996 Circulation pmid:8964113
Davì G et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. 2003 Circulation pmid:12810609
Patrignani P et al. Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 2000 Circulation pmid:10920066
Davì G et al. Oxidative stress and platelet activation in homozygous homocystinuria. 2001 Circulation pmid:11535567
Maree AO and Fitzgerald DJ Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. 2007 Circulation pmid:17452618
Cipollone F et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. 2002 Circulation pmid:12135935
Capone ML et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 2004 Circulation pmid:15037526
Eikelboom JW et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. 2002 Circulation pmid:11940542
Davì G et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. 1999 Circulation pmid:9892587
Cipollone F et al. Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methylprednisolone in unstable angina. 2003 Circulation pmid:12515743
Eikelboom JW et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. 2008 Circulation pmid:18838564
Larsson PT et al. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. 1994 Circulation pmid:8181117
Cattaneo M Letter by cattaneo regarding article, "incomplete inhibition of thromboxane biosynthesis by acetylsalicylic Acid: determinants and effect on cardiovascular risk". 2009 Circulation pmid:19546394
Nakamura A et al. Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. 2013 Circ. J. pmid:23676973
DeFilippis AP et al. Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction. 2013 Circ. J. pmid:23985963
Santilli F et al. Pentraxin 3 and Platelet Activation in Obese Patients After Gastric Banding. 2016 Circ. J. pmid:26632534
Gao F et al. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. 2011 Chin. Med. J. pmid:21740787
Tanaka S et al. High dose of inhaled fluticasone reduces high levels of urinary leukotriene E4 in the early morning in mild and moderate nocturnal asthma. 2003 Chest pmid:14605047
Obase Y et al. Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma. 1998 Chest pmid:9792572
Kurokawa K et al. Circadian characteristics of urinary leukotriene E(4) in healthy subjects and nocturnal asthmatic patients. 2001 Chest pmid:11742908
Obase Y et al. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. 2002 Chest pmid:11796443
Ferretti A and Flanagan VP Mass spectrometric evidence for the anomalous chemical behavior of 11-dehydrothromboxane B2. 1995 Chem. Phys. Lipids pmid:7586090
Helgason CM et al. Platelet aggregation and recruitment with aspirin-clopidogrel therapy. 2008 Cerebrovasc. Dis. pmid:18349532
Dippel DW et al. What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? 2004 Cerebrovasc. Dis. pmid:15026612
Martinuzzo ME et al. Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies. 2001 Br. J. Haematol. pmid:11564073
Coppola A et al. Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. 2005 Br. J. Haematol. pmid:16173969
Wallén NH et al. Effects of treatment with oral isosorbide dinitrate on platelet function in vivo; a double-blind placebo-controlled study in patients with stable angina pectoris. 1994 Br J Clin Pharmacol pmid:7946939
Floyd CN et al. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. 2014 Br J Clin Pharmacol pmid:25099258
Warner JH et al. Adaptive regression modeling of biomarkers of potential harm in a population of U.S. adult cigarette smokers and nonsmokers. 2010 BMC Med Res Methodol pmid:20233412
Wang ZY et al. Comparative study of platelet activation markers in diabetes mellitus patients complicated by cerebrovascular disease. 2001 Blood Coagul. Fibrinolysis pmid:11685040
Dharmasaroja PA and Sae-Lim S Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers. 2010 Blood Coagul. Fibrinolysis pmid:20689403
Bridges AB et al. Circadian variation of endothelial cell function, red blood cell deformability and dehydro-thromboxane B2 in healthy volunteers. 1991 Blood Coagul. Fibrinolysis pmid:1932530
Dharmasaroja PA et al. Aspirin nonresponders in patients with ischaemic stroke. 2013 Blood Coagul. Fibrinolysis pmid:23429255
Landolfi R et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. 1992 Blood pmid:1327286